Kura Oncology Inc
KURAHealthcare|Biotechnology|USA
$11.44
-0.63 (-5.22%)
Tangible Book
$1.22
Earnings Power
$4.33
Clinical Trials (23)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07007312 Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Acute Myeloid Leukemia (AML) | P3 | Recruiting | 1,300 | RCT, Double-blind | Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C) |
| NCT05848687 TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Lymphoblastic Leukemia | P1P2 | Recruiting | 90 | Open-label | Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib |
| NCT04067336 First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Advanced Malignant Neoplasm, Acute Myeloid Leukemia | P1P2 | Active | 263 | RCT, Open-label | Ziftomenib, Midazolam, Itraconazole |
| NCT06026410 KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC) | P1 | Recruiting | 300 | Open-label | Darlifarnib, Cabozantinib, Adagrasib |
| NCT06001788 Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | AML, AML With Mutated NPM1 | P1 | Recruiting | 171 | Open-label | Ziftomenib, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Granulocyte colony-stimulating factor |
| NCT05735184 A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation | P1 | Recruiting | 420 | Open-label | Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib |
| NCT06397027 A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias | Refractory Acute Leukemia, Pediatric Relapsed | P1 | Recruiting | 22 | Open-label | Ziftomenib, Venetoclax, Azacitidine |
| NCT06448013 A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia | Acute Myeloid Leukemia | P1 | Recruiting | 22 | Open-label | Venetoclax, Gemtuzumab, Ziftomenib |
| NCT06655246 A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer | P1 | Recruiting | 157 | Open-label | ziftomenib, imatinib mesylate |
| NCT06376162 Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia | Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia | P1 | Recruiting | 20 | Open-label | Ziftomenib, Cytarabine, Fludarabine |
| NCT02464228 Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy | Relapsed or Refractory Peripheral T-Cell Lymphoma | P2 | Completed | 65 | Open-label | Tipifarnib |
| NCT02779777 Tipifarnib in Subjects With Myelodysplastic Syndromes | Myelodysplastic Syndromes | P2 | Terminated | 16 | RCT, Single-blind | Tipifarnib |
| NCT06930352 Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy | Acute Myeloid Leukemia | P2 | Not Yet Recruiting | 70 | Open-label | Cytarabine, Hydroxyurea, Ziftomenib |
| NCT02383927 Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | P2 | Completed | 63 | Open-label | Tipifarnib |
| NCT03719690 Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy | HRAS Gene Mutation, HNSCC | P2 | Completed | 296 | Open-label | Tipifarnib |
| NCT02807272 Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia | Leukemia, Myelomonocytic, Chronic | P2 | Completed | 44 | Open-label | Tipifarnib |
| NCT04997902 Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | HNSCC | P1P2 | Completed | 45 | Open-label | Tipifarnib, Alpelisib |
| NCT07355335 Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML | KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML | P1 | Not Yet Recruiting | 24 | Open-label | Ziftomenib, Mezigdomide |
| NCT05693090 Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer | NSCLC | P1 | Withdrawn | — | Open-label | Tipifarnib, Osimertinib |
| NCT04865159 Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies | Advanced Solid Tumor | P1 | Terminated | 6 | Open-label | Tipifarnib |
| NCT03051035 First-in-Human Study of KO-947 in Non-Hematological Malignancies | Advanced Malignant Neoplasm | P1 | Terminated | 61 | Open-label | KO-947 |
| NCT05738538 Expanded Access to Ziftomenib | Acute Lymphoblastic Leukemia, With KMT2A Rearrangements, Acute Myeloid Leukemia, With NPM1 Mutations | AVAILABLE | — | — | ziftomenib | |
| NCT04809233 Expanded Access to Tipifarnib | HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) | AVAILABLE | — | — | Tipifarnib |